Compare iShares Core S&P 500 ETF (IVV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Merck & Co., Inc. — how do they compare? iShares Core S&P 500 ETF trades at $780.78 (market cap $897.20B), while Merck & Co., Inc. trades at $144.64 (market cap $351.28B). The key difference: iShares Core S&P 500 ETF is far larger — about 2.6× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Merck & Co., Inc. for 98 Days on average.
| IVV | MRK | |
|---|---|---|
Market Cap | $897.20B | $351.28B |
Volume | 4,580,672 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $156.43 |
52-Week Low | $634.93 | $82.49 |
Typical Hold Time | 46 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $779.68, down 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights mixed S&P 500 valuation signals, with earnings growth expected to slow in 2027 but historical seasonal patterns suggesting potential upside. The ETF's fundamentals reflect the index's aggregate metrics, with no company-specific financials reported.
Outlook remains cautiously optimistic given the bullish technical bias and index-level support, though risks include concentration in top holdings and macroeconomic headwinds. Investors gain diversified exposure to large-cap U.S. equities, but should monitor earnings trends and interest rate sensitivity.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
